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ABSTRACT
This study aimed to evaluate the clinical pharmacist interventions in reducing drug-related problems
(DRPs) in childhood acute lymphoblastic leukemia (ALL) patients in the Tangerang District General
Hospital, Banten, Indonesia. This study used a prospective analysis of patients with a pre-post design
between January-March 2017. The Pharmaceutical Care Network Europe (PCNE) (V6.2) pre-post
study system was used to identify the DRPs of 138 patients. The Pharmacist interventions were
addressed to physicians, patients, and other health professions to determine the effectiveness of
pharmacist interventions before and after the intervention. The number of identified DRPs was 177
problems and the identified types of DRP was 164 types. The pharmacist interventions significantly
decreased the DRPs from 177 to 10 DRPs (p<0.05) and type of DRPs from 164 to 10 types of DRPs
(p<0.05). Risk factors for nutritional status, type of ALL, comorbidities, number of drug items, and
type of treatments did not significantly affect (p>0.05) to the decreased of the number and type
of DRPs. Clinical pharmacist interventions able to reduce the number and type of DRPs and can
improve treatment outcomes in childhood ALL.
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INTRODUCTION
WHO data reported the prevalence of childhood cancers
is accounting for 0.5% to 4.6% of all cancers. The total
incidence rates of childhood cancer vary between 50 and
200 per million children worldwide. In general, leukemia
constitutes about a third of all cancer in childhood (WHO,
2017). A number of 11,000 cases of childhood cancer
have been reported each year in Indonesia and 1957
cases of acute lymphoblastic leukemia (ALL) in children
occurred in 15 hospitals in Indonesia around 2007-2012,
in which approximately 650 cases developed in Jakarta
(Ministry of Health of the Republic of Indonesia, 2015).
Most of the childhood cancer cases appear without
specific symptoms causing a delay in the diagnosis
of cancer. Inaccurate diagnosis of cancer, inadequate
equipment and medication in hospitals lead to disease
complications. The lack of cancer-related knowledge in
primary care providers also renders the effectiveness of
cancer treatment (Ministry of Health of the Republic of
Indonesia, 2015).
The incidence of childhood leukemia under the age of 15
years is about 4-4,5/100,000 children per year while the
highest frequency occurs at the age of 2-5 years (Basic
Health Research, 2013). The onset of acute lymphoblastic
leukemia (ALL) usually develop unexpectedly and can
lead to death if not treated properly. The appropriate
treatment increased the life expectancy of patients
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significantly as many as 96-99% of children could
achieve full remission, and 50-60% of patients had a
good prognosis (Dipiro et al., 2011 and Sabatine, 2014).
During the year 2010-2013, ALL is a disease with the
highest incidence and mortality in Indonesia (Ministry
of Health the Republic of Indonesia, 2015). The
previous study reported that all leukemia patients in
Yogyakarta, Indonesia had 35% refused treatment, 23%
experienced treatment-related deaths, 22% suffered
adverse conditions or relapsed, and 20% recovered from
illness (Mostert et al., 2010). That study illustrates the
current general situation in Indonesia (The OncologyHematology Work Coordination Unit, Association of
Indonesian Pediatricians, 2013).
Although the drug plays an important role in the healing
and prevention of illness, most patients develop drugrelated problems (DRPs). DRPs are conditions that
potentially affects the desired outcome of the therapy.
DRPs evolve immediately after administration of drug
therapy and might affect the patient’s clinical condition
that is associated with patient morbidity and mortality
(Pharmaceutical Care Network Europe, 2010). Many
studies showed the consequences of DRPs, which
include additional doctor visits, long-term treatments,
hospitalization, polypharmacy and emergency room care
(Baena et al., 2006).
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A study of DRPs in a children’s ward at Zewditu
Memorial Referral Hospital, Addis Ababa, Ethiopia
showed the incidence of DRPs was 31.6%. Dose-related
problems had a notable percentage about 45 (42.5%)
of all DRPs. Drug-drug interactions (DDIs) occurred
about 41 (38.7%), and undesirable drug reactions were 9
(8.5%) (Biarra et al., 2017).
The role of pharmacists in pharmaceutical care for
pediatric patients is to plan an optimal drug therapy by
considering pathophysiological changes, drug efficacy,
and specific toxicity. Therefore, pharmacists play a vital
role in detecting, preventing and overcoming drugrelated problems (Ministry of Health of the Republic
of Indonesia, 2009). This study was conducted to
evaluate the effect of clinical pharmacist’s intervention
in reducing the DRPs in pediatric acute lymphoblastic
leukemia treated with chemotherapy at referral hospitals
in Tangerang, Indonesia.
METHODS
This study was conducted in child ward of Tangerang
District General Hospital and carried out as prospective
design, a pre-post design before and after pharmacist’s
intervention over the period from January to March 2017.
The study was approved by the Ethics Committee of the
Faculty of Medicine University of Indonesia (No: 948 /
UN2.F1 / ETIK / 2016). The sampling was conducted by
purposive sampling and the selected sample was based
on inclusion criteria, i.e., patients who have DRPs aged
one month to <18 years old and undergo hospitalization
or one day care chemotherapy. The exclusion criteria
were relapsed childhood ALL patients and patients with
incomplete medical record data.
The drug therapy details, laboratory parameters and
demographic details of all inpatients were prospectively
reviewed by a clinical pharmacist. During ward
rounds, drug and dose selection, drug regimens and
patients’ drug use patterns were evaluated in order
to identify DRPs as per Version 6.2 of the PCNE
classification system. Pharmacist’s interventions
consisted of reporting and discussing identified DRPs
during interviews with various recipients, including
pediatrician, patients, pharmaceutical logistics clerks,
nurses and nutritionists. The type of intervention
was classified as either independent (i.e. specifically
tailored to an individual recipient) or concurrent (i.e.
provided to several or all recipients at the same time).
It is important to note that each DRP could be targeted
with more than one intervention. After the interventions,
the pharmacist continued monitoring the patient until
discharge, conducting further interventions as necessary
for any subsequent DRPs. The overall number of clinical
problems and the overall number and subtypes of DRPs
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before and after the intervention were calculated for
every patient. Data were analyzed using the Statistical
Package for the Social Sciences (SPSS), Version 23.0
(IBM Corp., Armonk, New York, USA). A Wilcoxon
signed rank test was used to assess the differences
between pre- and post-intervention DRPs. A Chi-squared
test was used to assess the relationship between DRPs
and risk factors such as nutritional status, type of ALL,
comorbidities, the number of drug items and type of care.
RESULTS AND DISCUSSION
Demographic and Clinical Data of Patients
A total of 138 patients had met the inclusion requirements
and had been recruited for the study, consisted of female
(52.9%) and male (47.1%). Patients were the age at
>5-10-years-old (44.2%), yet they mostly suffered at
the age of 4-years-old (17.4%). It is consistent with
the previous studies that indicated the incidence rates
of leukemia in children occurred at the age of 2-5
years (Widiaskara et al., 2010; Ministry of Health
of the Republic of Indonesia, 2011). Data on patient
characteristics were shown in Table 1.
This study showed that the number of high risks (HR)
ALL was more dominant (77.5%). It might be due to
the childhood ALL patients coming to the provincial
referral hospital in more severe conditions due to the
long initial diagnosis and referral process on the way up
to the hospital. There is a possibility of an increased in
cancer cells malignancy that often leads to a condition
of hyperleukocytosis (leukocyte count > 50,000/
mm3). In contrast, other studies reported the number of
standard risks (SR) childhood ALL is higher than inpatients at HR (Latamu et al., 2016). Another study at
Cipto Mangunkusumo Hospital, Jakarta, Indonesia, also
showed that 64.3% of the patients were SR childhood
ALL (Permatasari et al., 2009).
Our results also found that the most common types of
comorbidities were thrombocytopenia, anemia and,
diarrhea. It is similar with the characteristic clinical
symptoms of pediatric ALL, anemia (<7 g/dL) at 43%,
normochromic normocytic, thrombocytopenia (severe,
< 20,000 cells/mm3) at 28% of cases (Dipiro et al.,
2014). Diarrhea is one of the infections that can be
found in childhood ALL patients. The most common
cause of diarrhea is excessive intestinal motility, either
due to local irritation of the intestinal wall caused by
bacterial and viral infection or due to the emotional
stress. One of the main consequences of Leukemia is
the inability of the immune system to defend the body
from invasion of foreign matter. In leukemia, white
blood cell counts can reach as high as 500,000/mm3,
compared with a normal count of 7,000/mm3. However,
because most cells are abnormal or immature, they are
E-ISSN 2477-0612
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Table 1. Basic demographic and clinical data of patients (n=138 patients)
Characteristic

Category

Total (%)

Age

1-5 year-old
>5-10 year-old
>10-15 year-old
>15 -18 year-old

47 (34.1)
61 (44.2)
28 (20.3)
2 (1.4)

Sex

Male
Female

73 (52.9)
65 (47.1)

Nutritional status

Good nutrition
Malnutrition

132 (96.6)
6 (4.4)

ALL type

Standard risk
High risk

31 (22.5)
107 (77.5)

Comorbidity

1-3
>3

134 (97.1)
4 (2.9)

Drug used item

1-5
>5

116 (84.1)
22 (15.9)

Type of care

One-day care chemotherapy
Inpatient

112 (81.16)
26 (18.84)

not capable of performing their defense functions. As a
result, infection or severe bleeding is the most frequent
cause of death in leukemia patients. Bacteria/viruses
can easily invade people with immunosuppression. The
notorious cause of diarrhea is due to irritation from a
virus or bacterial infection in the distal bowel or colon
(Guyton and Hall, 2007). Besides of that, diarrhea may
result from damage of gastrointestinal mucosal cells
caused by chemotherapy. Antineoplastic drugs and
antimetabolite groups, especially methotrexate, also
have side effects on the digestive tract, bone marrow and
oral mucosa (Boussios et al., 2012). Stomatitis, diarrhea,
thrombocytopenia, leukopenia or any sudden decline in
leukocyte and thrombocyte counts indicates of treatment
discontinuation. It is done to prevent the fatal ulceration
of the gastrointestinal tract, infections, and hemorrhages
(Nafraldi, 2008).
Treatment of Acute Lymphoblastic Leukemia
Patients
The total number of drugs given to childhood ALL
patients in this study was 422 items consisting of
44 types of drugs. Methotrexate either intrathecal or
intravenously was commonly used at 31.3% due to the
most patients (81.2%) were undergo a maintenance
phase of chemotherapy which is given methotrexate
tablet once a week. The use of drugs was followed by
6-mercaptopurine (29.1%) and vincristine (3.1%). Most
of them received one to five items (84.1%), and the
others received more than five items (15.9%).
The study was found that 96.6% of childhood ALL has
good nutritional status. Nutrition status data was taken
E-ISSN 2477-0612

from the medical records that have been assessed by
the hospital’s nutrition department. Malnutrition has
a significant effect on ALL treatment outcomes. There
are several reasons for the decrease in nutrient intake,
one of them is the presence of cytokines such as alpha
necrosis tumors that cause anorexia. The effects of
pro-inflammatory cytokines have been investigated as
the cause of various metabolic phenomena in cancer.
Other causes of the reduced intakes of nutrients that
causing anorexia and gastrointestinal effects are the
high doses of chemotherapy drugs and radiotherapy that
leads to mucosal damaged or toxicity. Moreover, doseenhancing patterns, continuous infusion (versus bolus
dose), and combination chemotherapy treatment also
elevate the side effects. High doses of chemotherapy
often cause painful oral mucositis, which reduces the
nutritional intake of several weeks. The treatment effects
on gastrointestinal including esophagitis and enteritis
with malabsorption and diarrhea increased sensitivity
to bitterness, resulting in reduced the nutritional intake
and difficulty of oral supplementation (The OncologyHematology Work Coordination Unit-Association of
Indonesian Pediatricians, 2013; Mostert et al., 2010).
Identification of DRPs
Identification of DRPs was performed according to
PCNE classification system version 6.2 2010. A total of
177 DRPs were found, which 91.57% were actual DRPs
and the remaining 8.43% were potential. The mean DRP
per patient was 1.28 while the type of DRP was 164 types.
The average type of DRP that occurs per patient was 1.19.
The number of DRPs before pharmacist intervention was
shown in Figure 1 and the description sub-domain of
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Figure 1. Number of DRPs of patients in the study before pharmacist’s intervention (n=177 DRPs)

Figure 2. Sub-domain of DRPs of patients in the study before pharmacist’s intervention (n = 177 DRPs)
DRPs was shown in Figure 2. We also identified types
of DRPs with 61.02% were patient’s dissatisfaction with
the therapy they have received, 29.3% was non-allergic
effects, and 8.48% was the not optimal effects of drugs.
DRPs that occurred include the effectiveness of therapy
(9.04%), adverse drug reactions (ADRs) (29.94%),
treatment costs (0%) and other problems (61.02%). The
most common causes of DRPs were associated with
pharmaceutical logistics in which prescription drugs
were not available (62.1%), adverse events occurred in
patients (23.2%), and drug interactions (5.6%). Data on
number of DRPs and difference of DRPs before and after
receiving pharmacist intervention characteristics were
shown in Table 2.
The unavailable drug was methotrexate tablets used by
childhood ALL patients in the maintenance phase, even
though DPRs of methotrexate was the highest incidence

because it has been used in every phase of HR and SR
ALL chemotherapy. The duration of chemotherapy also
a significant cause of DRPs. In the maintenance phase,
chemotherapy regimens used methotrexate tablet once a
week for SR. The maintenance phase started at week 13
and ended at week 110, while at HR started in 18 weeks
and ended at week 118. Therefore, to overcome the
problems, we gave counseling on the non-availability
of methotrexate tablets and replaced the treatment with
alternatives using methotrexate intravenous.
The effectiveness of drug was evaluated by comparing
whether the dosage, method of use, interval, and
duration of use were suitable with the indication for the
childhood ALL patients in the literature or chemotherapy
protocol, without monitoring the blood levels of the
drug. The determination of DRPs in this study had
several limitations among other studies, for example
E-ISSN 2477-0612
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Table 2. Evaluation of decreased number of DRP after receiving pharmacist intervention
January-March 2017
Primary
problem

Code

Problems

Amount of DRPs
pre-intervention

Amount of
DRPs postintervention

Treatment
effectiveness

P 1.1
P 1.2
P 1.3
P 1.4

No effect of drug treatment/ therapy failure
Effect of drug treatment not optimal
Wrong effect of drug treatment
Untreated indication

0 (0%)
15 (8.48%)
0 (0%)
1 (0.66%)

0 (0%)
2 (1.13%)
0 (0%)
0 (0%)

Total

16 (9.04%)

2 (1.13%)

Adverse drug event (non-allergic)
Adverse drug event (allergic)
Toxic adverse drug-event

28 (15.82%)
7 (3.95%)
18 (10.12%)

6 (3.39%)
0 (0%)
2 (1.13%)

Total

53 (29.94%)

8 (4.52%)

Drug treatment more costly than necessary
Unnecessary drug-treatment

0 (0%)
0 (0%)

0 (0%)
0 (0%)

Total

0 (0%)

0 (0%)

Patient dissatisfied with therapy despite
optimal clinical and economic treatment
outcomes
Unclear problem/complaint. Further
clarification necessary

108 (61.02%)

0 (0%)

0 (0%)

0 (0%)

Total

108 (61.02%)

0 (0%)

177

10

Adverse
reactions

Treatment
costs

P 2.1
P 2.2
P 2.3

P 3.1
P 3.2

P 4.1
Others

P.4.2

Total of DRP Found
Difference of DRP before and after receiving pharmacist
intervention
there is no examination of allergy with skin pricks test
or measurement of specific immunoglobulin E (IgE)
levels in the blood to decide if the patient has allergic
adverse drug reactions (ADRs). Determination of
patients experiencing allergic ADRs could be measured
if there are signs and symptoms of a real allergy. For
example, red bumps appear in the skin that repeatedly
occur, eyelids and swollen lips, shortness of breath that
is not caused by other diseases, dry skin, redness as
well as itching recurring in typical locations such as the
cheek area, elbow folds, behind the knee, and based on
the results of a specialist skin examination. This study
also did not examine the levels of drugs in the blood to
evaluate potentially/suffering from toxic effects. The
determination of potentially/suffering patient’s toxic
effects was evaluated by checking whether the patient
receives drugs that are at the risk of organ toxicity
according to the literature and performing laboratory
investigation of related organ function.
Evaluation of Pharmacist Interventions
In this study, most of the clinical pharmacist interventions
had been well received by health professions and
E-ISSN 2477-0612

167 (94.35%)

patients (94.9%) in Tangerang District General Hospital.
The target of dominant interventions was physicians,
patients, nurses, and the pharmaceutical department
which amounted to 93.6% of 177 DRPs. Clinical
pharmacist interventions were performed to reduce the
incidence of DRPs and have a positive effect on drug
therapy services in childhood ALL patients, but not all
interventions were accepted and performed in this study.
A total of nine DRPs were not intervened because four
of them were not intervened by pharmacists, merely by
doctors. The other two DRPs were not intervened because
no electrolyte examination was performed to monitor
the risk of hypocalcemia caused by the interaction of
dexamethasone (corticosteroid) with furosemide (loop
diuretic). Three interventions on DRPs were also not
accepted by doctors because two interventions could
not be performed due to unavailability of facilities and
infrastructure for a liver biopsy to monitor the risk of
methotrexate hepatotoxicity after accumulation dose
of 4 g followed by the increase of 1.5 g doses. Another
one intervention was not accepted regarding the clinical
condition of patients suffering from hypocalcemia due
to Lysis Syndrome Tumors (TLS). The physician was
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Table 3. Change of number and type of DRPs with risk factors of patients after receiving pharmacist intervention
(n=138 patients)

Risk Factor

Category

Change in number of
DRP
Decreased Constant/
Increased
(%)
(%)

Total

p
value

Change in type of DRP
Decreased
(%)

Constant/
Increased
(%)

Total

P value

Nutritional
status

Good
Malnutrition

131 (99.2)
1 (0.8)

6 (100)
0 (0)

137
1

0.957

131 (99.2)
6 (100)

1 (0.8)
0 (0)

132
6

0.085

ALL type

SR
HR

31 (100)
106 (99.3)

0 (0)
1 (0.9)

31
107

0.775

31 (100)
105 (98.1)

0 (0)
2 (1.9)

31
107

0.600

Comorbidity

1-3
>3

133 (99.3)
4 (100)

1 (0.7)
0 (0)

134
4

0,971

132 (98.5)
4 (100)

2 (1.5)
0 (0)

134
4

0.943

Number of
drugs used

1-5
>5

116 (100)
21 (95.5)

0 (0)
1 (4.5)

116
22

0.159

116 (100)
20 (90.9)

0 (0)
2 (9.1)

116
22

0.024*

Type of care

ODC
Inpatient

112 (100)
25 (96.2)

0 (0)
1 (3.8)

112
26

0.118

112 (100)
24 (92.3)

0 (0)
2 (7.7)

112
26

0.034*

SR = standard risk, HR = high risk, ODC = One-day Care Chemotherapy, *statistically significant (p<0.05)

worried if the intravenous calcium given, the TLS would
be worsening.
Bivariate analysis was conducted using the Wilcoxon
Sign Rank test to determine the effect of clinical
pharmacist intervention on the number and type of DRPs
before and after the intervention. The results showed that
there was a notable change in the number of DRPs with
the mean value before the intervention was decreased
from 1.28 to 0.07 after the intervention. Moreover,
the reduction of mean value in the type of DRPs also
occurred at 1.19 before the intervention to 0.07 after
the intervention. Evaluation of decreased number and
type of DRP after receiving pharmacist intervention was
shown in Table 2.
The Fisher exact bivariate analysis was used to identify
correlations between nutritional status, type of ALL,
comorbidity, the number of drug items, and type of
care that could decrease the number and type of DRPs
of childhood ALL before and after clinical pharmacist
intervention. The change of number and type of DRPs
with risk factors of patients after receiving pharmacist
intervention was shown in Table 3. The results showed
that the number of drugs used and the type of care
significantly affected the decrease in the type of DRPs
(p<0.05). Several previous studies showed the amount of
drug administered to patients is an important risk factor
for the occurrence of DRPs (Ibrahim N et al., 2013;
PCNE, 2010; Rashed AN et al., 2014; Rashed AN et al.,
2012). More complex drug therapy due to the presence

of disease complications leads to a higher risk of DRPs
such as side effects, drug interactions, medication errors,
and noncompliance. It occurs because in this case the
more drugs will be consumed.
Logistic regression multivariate analysis was conducted
to see the most dominant risk factors for the decrease
type of DRPs. The test results showed a none significant
difference of risk factor effect on the decrease type of
DRPs (p>0.05). This study reported that the decrease in
the number and type of DRPs in childhood ALL patients
in Tangerang District General Hospital is due to the
success of the pharmacist intervention in preventing
potential DRPs and completing the actual DRPs.
CONCLUSION
This prospective study found that DRPs among
childhood ALL patients were significantly reduced
following a clinical pharmacist intervention amount to
94.35%. The number of DRPs identified with childhood
ALL inpatients and patients who underwent one day care
chemotherapy at the Tangerang District General Hospital
was 177 problems which consisted of 164 types of
problems. DRPs that occurred include the effectiveness
of therapy (9.04%), adverse drug reactions (ADRs)
(29.94%), treatment costs (0%) and other problems
(61.02%). The risk factors of nutritional status, type of
LLA, number of comorbidities, number of drug items
and type of treatment did not give a significant effect to
reduce the number and type of DRPs (p>0.05). These
E-ISSN 2477-0612
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findings indicate that a pharmacist intervention can
optimize therapy of childhood ALL patients.

with chronic kidney disease. Pediatric Nephrology,
28(1), 25–31.
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